Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Sublocade (RBP-6000) in Opioid-Dependent Subjects
NCT03002961Phase 1Completed
- Sponsor
- Indivior
- Start
- Jul 2012
- Primary completion
- Feb 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (4 cohorts), sponsored by Indivior. Primary endpoints: Frequency of Adverse Events at Day 150, Pharmacokinetic Concentrations at Day 150 and 1 more. Started Jul 2012; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03002961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002961.